Short-and mid-term intravascular ultrasound analysis of the new zotarolimus-eluting stent with durable polymer: Results from the RESOLUTE trial

Circulation Journal

Volumn 74, Issue 10, 2010, Pages 2097-2102

  Waseda, Katsuhisa ^a   Ako, Junya ^a   Yamasaki, Masao ^a   Koizumi, Tomomi ^a   Ormiston, John ^b   Worthley, Stephen G ^c   Whitbourn, Robert J ^d   Walters, Darren L ^e   Honda, Yasuhiro ^a   Meredith, Ian T ^f   Fitzgerald, Peter J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e THE PRINCE CHARLES HOSPITAL   (Australia)

^f MONASH MEDICAL CENTRE   (Australia)

Author keywords

Coronary artery disease; Intravascular ultrasound; Zotarolimus eluting stent

Indexed keywords

POLYMER; ZOTAROLIMUS;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS;

AGED; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOINTIMA; POLYMERS; SIROLIMUS; TIME FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 77958043892     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0063     Document Type: Article

References (33)

1. Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute firstin- man trial. EuroIntervention 2007; 3: 50-53.
2. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, et al. Clinical and angiographic results with the nextgeneration resolute stent system: A prospective, multicenter, firstin- human trial. J Am Coll Cardiol Intv 2009; 2: 977-985.
3. Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, et al. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: An intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 2002; 106: 1788-1793.
4. Honda Y. Drug-eluting stents: Insights from invasive imaging technologies. Circ J 2009; 73: 1371-1380.
5. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
6. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003; 107: 381-383.
7. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Shofer JJ, et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel- eluting coronary stent: The SPIRIT II trial. EuroIntervention 2006; 2: 286-294.
8. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxeleluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299: 1903-1913.
9. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus, paclitazel-eluting coronary stent in patients with stenosis in native coronary arteries: The Nobori 1 trial. EuroIntervention 2007; 2: 426-434.
10. Grube E, Sievert H, Hauptmann KE, Mueller R, Gerckens U, Buellesfeld L, et al. Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results. EuroIntervention 2008; 4: 71-76.
11. Hasegawa T, Ako J, Koo BK, Miyazawa A, Sakurai R, Chang H, et al. Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: Intravascular ultrasound results of the AXXENT trial. Catheter Cardiovasc Interv 2009; 73: 34-41.
12. Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, et al. Detailed intravascular ultrasound analysis of Zotarolimuseluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 2007; 100: 818-823.
13. Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008; 155: 108-113.
14. Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, et al. Intravascular ultrasound results from the ENDEAVOR IV trial: Randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol Intv 2009; 2: 779-784.
15. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: The Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005; 46: 253-260.
16. Kuroda N, Kobayashi Y, Nameki M, Kuriyama N, Kinoshita T, Okuno T, et al. Intimal hyperplasia regression from 6 to 12 months after stenting. Am J Cardiol 2002; 89: 869-872.
17. Hong MK, Lee CW, Kim YH, Lee BK, Kim MK, Yang TH, et al. Two-year follow-up intravascular ultrasound analysis after bare metal stent implantation in 120 lesions. Catheter Cardiovasc Interv 2005; 65: 247-253.
18. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, et al. Extracellular matrix changes in stented human coronary arteries. Circulation 2004; 110: 940-947.
19. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-2011.
20. Nakamura M, Abizaid A, Hirohata A, Honda Y, Sousa JE, Fitzgerald PJ. Efficacy of reduced-dose sirolimus-eluting stents in the human coronary artery: Serial IVUS analysis of neointimal hyperplasia and luminal dimension. Catheter Cardiovasc Interv 2007; 70: 946-951.
21. Meredith I, Ormiston J, Whitbourn R, Kay P, Muller D, Bonan R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine- encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 2005; 2: 157-164.
22. Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, et al. Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent. Am J Cardiol 2007; 99: 1403-1408.
23. Waseda K, Hasegawa T, Ako J, Honda Y, Grube E, Whitbourn R, et al. Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: Pooled IVUS results from the ZoMaxx I and II trial. Circ J 2010 (unpublished).
24. Shimohama T, Ako J, Yamasaki M, Otake H, Tsujino I, Hasegawa T, et al. SPIRIT III JAPAN versus SPIRIT III USA: A comparative intravascular ultrasound analysis of the everolimus-eluting stent. Am J Cardiol 2010; 106: 13-17.
25. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: A serial intravascular ultrasound analysis. J Am Coll Cardiol 2005; 46: 1002-1005.
26. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, et al. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113: 414-419.
27. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: An intravascular ultrasound analysis. Circulation 2003; 108: 2747-2750.
28. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: Insights from the randomized TAXUS II trial. Circulation 2005; 111: 900-905.
29. Weissman NJ, Ellis SG, Grube E, Dawkins KD, Greenberg JD, Mann T, et al. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: A volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. Eur Heart J 2007; 28: 1574-1582.
30. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
31. Feres F, Costa JR Jr, Abizaid A. Very late thrombosis after drugeluting stents. Catheter Cardiovasc Interv 2006; 68: 83-88.
32. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115: 2426-2434.
33. Lee SE, John SH, Lim JH, Rhew JY. Very late stent thrombosis associated with multiple stent fractures and peri-stent aneurysm formation after sirolimus-eluting stent implantation. Circ J 2008; 72: 1201-1204.